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Abstract—Prevention and rehabilitation of hearing loss and 
tinnitus, the two most commonly awarded service-connected 
disabilities, are high priority initiatives in the Department of 
Veterans Affairs (VA). At least 4,000 Veterans, most with sig-
nificant hearing loss, will receive cisplatin this year, with more 
than half sustaining permanent hearing shift and nearly 40% 
developing new tinnitus. With improved survivability follow-
ing  cancer  treatment,  Veterans  treated  with  cisplatin  are 
approached with the dual goals of effective treatment and pre-
served quality of life. This article describes COMP-VA, a com-
prehensive ototoxicity monitoring program developed for VA 
patients receiving cisplatin. The program includes an individu-
alized pretreatment prediction model that identifies the likeli-
hood of hearing shift given cisplatin dose and patient factors. It 
supports  both  manual  and  automated  hearing  testing  with  a 
newly developed portable audiometer capable of performing 
the recommended procedures on the chemotherapy unit during 
treatment. It also includes objective methods for identifying 
outer  hair  cell  changes  and  predicting  audiogram  changes 
using  distortion-product  otoacoustic  emissions.  We  describe 
this program of evidence-based ototoxicity monitoring proto-
cols using a case example to give the reader an understanding of 
how this program would be applied, along with a plan for future 
work to accomplish the final stages of program development.
Key  words:  aural  rehabilitation,  chemotherapy,  cisplatin, 
COMP-VA, distortion-product otoacoustic emissions, DPOAE,
hearing, OtoID, ototoxicity monitoring, sensitive range for 
ototoxicity.
INTRODUCTION
Prevention and rehabilitation of hearing loss and tin-
nitus are high priority initiatives in the Department of 
Veterans  Affairs  (VA).  In  the  last  decade,  more  than 
33,000  Veterans  nationally  were  treated  with  cisplatin 
chemotherapy at VA medical centers (VAMCs) (VA Infor-
matics  and  Computing  Infrastructure  database,  accessed 
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2012 May). Cisplatin is an antineoplastic agent used for 
the  treatment  of  a  variety  of  adult  cancers,  including 
bladder, testicular, gynecologic, head and neck, and lung. 
If trends continue, more than 4,000 Veterans will receive 
cisplatin this year, with more than 50 percent sustaining a 
permanent hearing shift and 39 percent developing new 
tinnitus [1–3]. Importantly, in our experience, the average 
age  of  Veterans  entering  treatment  is  60  yr  and  most 
report  a  history  of  significant  noise  exposure  [4–5], 
which accounts for the high rate of preexisting hearing 
loss in this population. It is well documented that hearing 
loss adversely impacts quality of life [6]; psychosocial 
functioning [7]; and one’s ability to obtain, process, and 
understand basic health information [8]; therefore, it is an 
undeniably important side effect to monitor during che-
motherapy.  Furthermore,  health-related  quality  of  life 
concerns are important to oncologists because improved 
treatments and early diagnoses have increased long-term 
cancer survivability. The approach of VA is to provide 
cancer management that is patient centered and directed 
toward improving the quality of life following treatment.
Within the inner ear, cisplatin primarily damages the 
cochlea, resulting in permanent, usually bilateral, high-
frequency  sensorineural  hearing  loss  in  approximately 
60 percent of adults treated with the drug [9]. This dam-
age occurs in a relatively orderly manner of base (high 
frequency) to apex (low frequency) destruction [10] pri-
marily of the outer hair cells, which are sensory receptor 
cells that provide for the large dynamic range and exact-
ing frequency selectivity that characterizes human hear-
ing. Damage also occurs to the marginal cells of the stria 
vascularis [11–14], which provides the electrochemical 
drive for the outer hair cells and spiral ganglion cells of 
the auditory nerve. A main mechanism of cisplatin oto-
toxicity is associated with the production of free radicals 
[15]. Overabundance of these unstable molecules over-
loads  intracellular  antioxidant  enzymes  and  leads  to  a 
cascade of damaging oxidative reactions and upregula-
tion  of  programmed  cell  death.  Depleting  the  natural 
defense system of cells leaves them especially suscepti-
ble to further ototoxic damage with each additional treat-
ment. The resultant peripheral hearing loss from this cell 
damage has been shown to be dose dependent in both 
animals [11] and humans [16].
Currently, only a small fraction of Veterans undergo-
ing chemotherapy with cisplatin are systematically moni-
tored  for  signs  of  ototoxicity.  Too  often,  Veterans  in 
treatment are asked to arrange for audiological testing 
once debilitating hearing loss is already apparent to the 
patient or treatment team. This testing must then be coor-
dinated with a patient’s already overburdened treatment 
schedule and into audiology clinic time slots that are rou-
tinely  scheduled  months  in  advance.  Further,  these 
appointments include lengthy diagnostic testing when a 
narrowly focused hearing screening done at each cispla-
tin-treatment visit would seem to be a better approach.
Nearly 30 yr of prospective ototoxicity monitoring 
and  research  by  the  VA  Rehabilitation  Research  and 
Development (RR&D) National Center for Rehabilitative 
Auditory Research (NCRAR) have shown that education 
and frequent communication with the monitoring audiolo-
gist improve the likelihood that oncologists will seek out 
and use information about ototoxic hearing changes for 
purposes of fine-tuning chemotherapy, when medically 
appropriate, to avoid disabling hearing loss. It has also 
become clear that audiology equipment and staffing limi-
tations need to be overcome in order to consistently iden-
tify  those  patients  who  face  the  greatest  risk  for 
preventable hearing loss and to support those who need 
extra help and motivation to access VA’s comprehensive 
range of hearing loss and tinnitus rehabilitation services. 
Further,  the  VA’s  existing  mechanisms  for  tracking 
patients throughout the system need to be exploited in 
order to ensure patients receive the audiological services 
they may need at various stages of cancer treatment and
survivorship.
The purpose of this article is to report on a complete 
program of evidence-based ototoxicity monitoring proto-
cols, the comprehensive ototoxicity monitoring program 
for VA (COMP-VA), developed at the NCRAR. COMP-
VA was designed to achieve a range of customizable clini-
cal objectives and to test all patients during treatment
regardless of how sick they are or their ability to reliably 
take a hearing test using conventional methods. This pro-
gram includes an individualized pretreatment prediction 
model that identifies the likelihood of hearing shift from 
cisplatin and supports both manual and automated hear-
ing testing with a newly developed portable audiometer 
capable of performing the recommended procedures on 
the chemotherapy unit during treatment. Also included 
are two objective test methods for identifying outer hair 
cell changes and predicting audiogram changes using dis-
tortion-product  otoacoustic  emissions  (DPOAEs).  The 
primary goal of COMP-VA is early detection of ototoxic-
ity in order to optimize both audiological outcomes and 
therapeutic  management  of  patients  receiving  cisplatin 83
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chemotherapy. This goal is to be accomplished using a 
team-based  approach  made  possible  in  large  part  by 
delivering COMP-VA services chairside on the oncology 
treatment unit.
METHODS
Programmatic Research Supporting Proposed Protocols
Serial Hearing Testing Using OtoID Portable Audiometer
COMP-VA  is  designed  to  be  administered  on  the 
chemotherapy  treatment  unit  just  prior  to  treatment 
(chairside). This eliminates the need for patients to make 
additional  trips  to  the  VA  and  the  need  for  scheduled 
hearing evaluations in the audiology clinic. To accom-
plish this, researchers at the NCRAR designed and engi-
neered  a  portable  ototoxicity  identification  device,  the 
OtoID,  that  can  provide  reliable  and  accurate  hearing 
thresholds on the hospital ward during treatment [17].
The  OtoID  portable  audiometer  is  comprised  of  a 
touch screen computer module, Sennheiser HDA200 cir-
cumaural headphones (Sennheiser Electronic Corp; Old 
Lyme, Connecticut) modified with ambient noise monitor-
ing microphones and custom audiometric testing software.
Unlike most commercially available portable audiometers,
the OtoID is capable of obtaining air conduction thresh-
olds at 500–20,000 Hz in 1/6th octave intervals with a 
dynamic range of 115 dB (10 to 105 dB). The OtoID 
meets or exceeds all American National Standards Insti-
tute (ANSI) S3.6–2010 class 4 and high frequency audi-
ometer  specifications  for  reference  equivalent  threshold 
sound  pressure  levels  (SPLs),  frequency  accuracy  and 
purity, attenuator linearity and rise/fall characteristics, and 
absence  of  unwanted  acoustic  signals  [18].  A  detailed 
description of the OtoID is provided in Jacobs et al. [18].
The  device  has  both  manual  (audiologist-directed 
testing) and automated (patient self-testing) modes. Figure 1
shows the OtoID being used for testing a Veteran in the 
automated mode. The automated mode prompts the user 
when  headphone  placement  is  incorrect  and  employs 
catch trials to achieve bias-free threshold estimates. Pure-
tone threshold results for each patient are stored in the 
OtoID, which has the capability to recall previous test 
results via a patient identifier (e.g., a Health Insurance 
Portability  and  Accountability  Act  of  1996  [HIPAA]-
compliant patient number). Additionally, the OtoID mea-
sures the ambient room noise at 
Figure 1.
Veteran using OtoID in automated (self-test) mode. Veteran is 
alerted to upcoming listening interval. Test tone is either played 
or catch trial occurs in which no tone is played. Patient is then 
instructed to respond via touch screen whether or not tone was 
heard. Earphones shown are Sennheiser HDA 200. Reprinted 
from Dille et al. [17].
earphone level before 
each  tone  presentation.  If  the  ambient  noise  exceeds 
ANSI  S3.1–1999  maximum  permissible  ambient  noise 
levels  (MPANLs),  the  tone  is  not  presented  and  the 
patient is instructed to either wait until the room is quiet 
or move to a quieter location.
Ongoing  development  of  the  OtoID  includes  the 
secure exchange of information between the device and 
the VA’s computerized patient records system and tele-
health  capabilities.  Sending  HIPAA-compliant  results 
from the OtoID built-in cell phone modem to a VA email 
address via secure text message is nearly complete. Auto-
mated testing combined with telehealth capabilities pro-
vides major advantages of the OtoID over current modes 
of ototoxicity monitoring. The automated test mode saves 
audiological professional time by having the patient con-
duct the behavioral hearing screening portion of the moni-
tor visit. Once the patient completes self-testing and the 
results are received in the audiology clinic, the audiolo-
gist can then travel to the treatment unit, complete addi-
tional  tests  (otoscopy  and  tympanometry,  screen-fail 
follow-up testing if necessary), and discuss results with 
the patient and the oncology team, ensuring that fully 
informed and timely treatment decisions can be made.
Behavioral Hearing Screening Using COMP-VA
Ototoxic damage must be detected by assessing audi-
tory function directly. Standard air conduction testing in 84
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conventional and extended high frequencies is possible 
using the OtoID. However, the sensitive range for ototox-
icity (SRO) technique [19] is also supported by COMP-
VA. The SRO technique is proposed as the behavioral 
hearing test method of choice for ototoxicity monitoring, 
as long as the Veteran is able to provide reliable hearing 
results despite the exhaustion caused by chemotherapy 
treatment. The SRO technique was designed to identify 
hearing shifts within an individualized range of relatively 
high frequencies so that treatment changes can be consid-
ered, if deemed necessary, to prevent hearing loss from 
spreading to the frequencies considered most important 
for understanding speech (those up to 4,000 Hz).
The SRO is determined based on each patient’s pre-
exposure  hearing  and  consists  of  seven  frequencies 
spaced 1/6-octave apart, spanning 1 octave near a patient’s
operationally defined high frequency hearing limit. Sig-
nificant hearing shifts during ototoxicity monitoring have 
been defined by the American Speech-Language-Hearing 
Association (ASHA) [20] as a 20 dB decrease at any one 
test frequency, a 10 dB decrease at any two adjacent test 
frequencies, or the loss of response at any three consecu-
tively  tested  frequencies  where  responses  were  previ-
ously obtained. ASHA’s criteria for a significant hearing 
shift when used with the SRO result in a reliable test 
[5,18]. The SRO technique is also sensitive (94% detec-
tion) regardless of whether the SRO falls above 8,000 Hz 
[19,21] or below 8,000 Hz [4]. The theorized basis for 
this high sensitivity is that the high frequency-coded base 
is  the  most  physiologically  vulnerable  area  within  the 
cochlea to cisplatin-related damage, and this damage pro-
gresses from base to apex.
Currently, most ototoxicity programs monitor in the 
conventional frequency range only, even though numer-
ous studies show greater sensitivity is achieved by testing 
frequencies above 8,000 Hz [22]. For example, one clini-
cal  study  showed  that  if  only  conventional  frequency 
testing (8,000 Hz) were used, 36 percent of initial (early 
detection)  changes  would  have  gone  undetected  [4], 
potentially missing the opportunity to prevent changes in 
the more functionally critical conventional frequencies. 
Further, use of the SRO screening protocol together with 
tests to rule out ear disease or obstruction (otoscopy, tym-
panometry) reduces testing time substantially in compari-
son to the full diagnostic evaluation that is commonly 
done, which includes otoscopy, tympanometry, air and 
bone  conduction,  and  speech testing.  Extensive  audio-
metric evaluations, typically done in the audiology clinic, 
are best saved until the patient has finished treatment and, 
perhaps, is ready to pursue hearing aid amplification.
We have recently confirmed that the risk for hearing 
shift from cisplatin is primarily related to the cumulative 
drug dose and, established in three separate data sets, that 
patients with better preexposure hearing have a greater 
risk of hearing change within the SRO at a given dose 
compared with patients with worse preexposure hearing 
[1–2,23]. Previous studies that examined extent of preex-
posure hearing as a potential risk factor for ototoxicity 
have conflicting results [24–25]. Differences across stud-
ies can be understood in terms of the differences in test-
ing methodology, specifically the different test frequency 
ranges used. Hearing tests lose sensitivity for subjects 
with  good  preexposure  hearing  when  testing  does  not 
include  frequencies  near  the  high  frequency  hearing 
limit. The increased vulnerability of the cochlea near its 
base, i.e., more hearing loss per unit cisplatin dose, was 
likely masked in previous studies by the decreased sensi-
tivity of conventional frequency testing for subjects with 
good preexposure hearing.
DPOAE Screening Using COMP-VA
In their respective clinical guidelines for ototoxicity 
monitoring, ASHA and the American Academy of Audi-
ology  (AAA)  have  proposed  that  both  behavioral  and 
nonbehavioral (objective) measures of auditory function 
be routinely used at the baseline evaluation because it is 
not clear which patients will become unable to provide 
reliable behavioral thresholds during treatment [20,26]. 
By  our  estimation,  at  least  30 percent of patients who 
receive  chemotherapy  do,  in  fact,  become  unable  to 
respond reliably during testing [27–28]. Using data from 
our  recently  completed  ototoxicity  research  project  at 
NCRAR, 50 of the 118 (41%) study subjects treated with 
cisplatin became untestable at some point in their treat-
ment  due  to  fatigue,  illness,  disease  progression,  or 
unwillingness to go to a sound suite for testing [2].
DPOAEs  are  objective  measures  able  to  identify 
cochlear  changes  associated  with  ototoxicity  [29–30]. 
DPOAEs depend on the physiological status of the outer 
hair cells, which are the initial site of ototoxic damage 
and, therefore, should be sensitive to hearing shifts [31]. 
DPOAEs are elicited using two tones that are close in fre-
quency  and  presented  simultaneously.  Responses  are 
influenced by hearing loss at the DPOAE frequency (2f1-
f2), the eliciting frequencies (f1 and f2, where f1 < f2), and 
comparatively higher frequencies coded by more basal 85
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cochlear  regions  [29,32–33].  Although  current  ASHA 
and  AAA  guidelines  urge  that  DPOAE  testing  be 
included  programmatically,  little  guidance  is  currently 
given  as  to  how  to  interpret  the  findings.  COMP-VA 
addresses this information gap.
One proposed DPOAE screening protocol is analo-
gous to the behavioral SRO technique in that it includes 
an initial broad frequency sweep done in 1/6-octave steps 
to  identify  the  highest  frequency  at  which  a  valid 
response of +6 signal-to-noise ratio can be measured fol-
lowed  by  additional  monitoring  of  several  frequencies 
near this limit at each chemotherapy treatment. Using a 
machine learning paradigm, we established that DPOAE 
shift metrics, obtained by comparing DPOAE baseline 
results to monitoring results, alone are sensitive predic-
tors  of  hearing  change  in  the  SRO  region,  but  when 
DPOAEs  are  combined  in  a  multivariate  model  with 
cumulative drug dose and baseline hearing levels, sensi-
tivity increases without causing unacceptably high false 
positive rates. In the multivariate model, DPOAE testing 
has proven to be sensitive to early ototoxic hearing shift 
using either input-output (I/O) intensity functions, i.e., 
decrease in level while holding frequency constant (area 
under  the  Receiver  Operating  Characteristic  curve 
[AUC] = 0.90) [22], or using fine step frequency mea-
sures, i.e., small frequency changes while holding inten-
sity  constant  (AUC  =  0.79 )  [2].  Providing  objective 
techniques for identifying shifts in behavioral pure-tone 
thresholds when a patient is unable to provide reliable 
hearing test results, due to extreme illness or fatigue char-
acteristic of chemotherapeutic treatment, is a very impor-
tant and often overlooked programmatic component.
Another proposed DPOAE protocol involves the use 
of test-retest reference limits based on normal variability 
in serial DPOAE level plotted as a function of f2 fre-
quency  levels  obtained  in  a  nonexposed  (to  cisplatin) 
group  of  Veteran  research  participants.  DPOAE  level 
shifts  obtained  during  ototoxicity  monitoring  that  are 
greater than the decibel shift that marks the upper 90th 
percentile from the reference population identify a clini-
cally significant DPOAE change [34]. Because there is 
no commonly accepted gold standard of outer hair cell 
damage  in  humans,  test  accuracy  can  never  be  com-
pletely known for this method. However, a false positive 
rate of DPOAE change can be estimated for a tester or 
group of testers using group variability from a nonex-
posed control group.
Even though many Veterans have preexisting hearing 
loss,  most  have  DPOAEs  that  can  be  monitored  for 
changes. In a prior study in which we examined DPOAEs 
among  individuals  with  confirmed  behavioral  hearing 
shifts  following  cisplatin  administration,  most  subjects 
(82/90 or 91%) had DPOAEs that were able to be suc-
cessfully  monitored  for  changes  [3].  Importantly,  in  a 
separate trial investigating DPOAE test performance for 
detecting ototoxicity, only 10 percent of ears had to be 
excluded for a lack of DPOAEs at baseline [2]. Experi-
ence has shown that DPOAE measures are maximally 
sensitive to ototoxicity if they are within one octave of 
the  behaviorally  tested  SRO  [3].  In  practice,  we  have 
found  that  there  are  many  instances  in  which  drug-
induced  pure-tone  threshold  shifts  are  restricted  to  a 
DPOAE  frequency  range  that  did  not  have  a  valid 
response at the baseline test session. In such cases, we 
have  found  that  DPOAEs  obtained  at  comparatively 
lower f2 frequencies are still useful for predicting hearing 
shifts, either because DPOAEs are sensitive to preclinical 
damage or are influenced by threshold shifts at compara-
tively higher frequencies than the eliciting primaries [2].
Effect of Ototoxicity Monitoring on Veterans: 
Case Studies
Below, we describe ototoxicity in two patients seen 
as part of our research on ototoxicity monitoring at the 
Portland  VAMC.  For  these  individuals,  chemotherapy 
treatments resulted in hearing shifts before the treatment 
was completed. One patient opted to change medication; 
the other patient’s disease necessitated that he continue 
with the planned regimen. Associated audiometric data 
for the patient described in case study 1 are presented in 
the “Clinical Objectives for COMP-VA” section.
Case Study 1
This patient is a 63 yr-old male treated for squamous 
cell carcinoma of the right base of tongue (stage IVa) 
with lymph node involvement. The planned chemotherapy
regimen included three doses of cisplatin at 100 mg/m2
on days 1, 22, and 43 with concurrent head and neck radia-
tion over 7 wk. An audiometric baseline evaluation was 
completed, at which time he presented with normal hear-
ing through 4,000 Hz sloping to a moderate loss of hear-
ing  at  6,000  and  8,000  Hz  in  both  ears.  His  high 
frequency limit of hearing was 12,500 and 11,200 Hz in 
the right and left ears, respectively. He reported bilateral 
intermittent tinnitus that was not bothersome. Otoscopy 86
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and tympanometry were normal bilaterally. Three weeks 
after his first dose (cumulative dose = 190 mg) and just 
before his second dose, a monitor evaluation revealed an 
ASHA-significant hearing change (average +10 dB shift) 
at 10,000 to 12,500 Hz in the right ear with normal otos-
copy  and  tympanometry.  The  left  ear  SRO  remained 
unchanged, as was his baseline tinnitus. A “screen fail-
ure” follow-up audiogram indicated the hearing shift was 
confined to the ultra-high frequencies in one ear. Oncol-
ogy was notified of these early unilateral hearing changes 
outside the speech frequency range and their decision was 
to continue with the second cisplatin dose. Three weeks
after his second dose and just before infusion with his third
dose  (cumulative  dose  =  38 0  mg),  ASHA-significant 
hearing change in the right ear expanded to include the 
4,000  to  12,500  Hz  frequency  range  (average  +25  dB 
shift) with no response to tones above 10,000 Hz. There 
was a concomitant +25 dB average shift in hearing in the 
left ear from 4,000 to 11,200 Hz, and middle ear function 
remained normal bilaterally. He now reported more fre-
quent tinnitus. Again, the oncology team was notified of 
the test results. At this point, the oncology nurse practi-
tioner  and  audiologist  together  counseled  the  patient 
regarding the potential for further hearing changes if he 
continued treatment with cisplatin versus the option of 
changing to a less toxic chemotherapy drug, but with an 
undetermined effect on treatment efficacy. The audiolo-
gist explained options for aural rehabilitation, including 
the use of hearing aids. The oncology team was encour-
aged  by  the  efficacy  of  treatment  to  this  point.  This 
patient-centered care approach involving both oncology 
and audiology resulted in the patient having the knowl-
edge to make an informed decision regarding his care. He 
chose to preserve his hearing, and the oncologist changed 
his chemotherapy drug to carboplatin, a chemotherapy 
drug associated with less toxicity, for his last dose. The 
patient underwent imaging 3 mo following his last treat-
ment, which indicated the cancer that had spread to the 
lymph  nodes  was  no  longer  present,  and  endoscopy 
revealed the base of tongue primary cancer had regressed 
completely. Audiological follow-up with the patient was 
remarkable for otalgia, a retracted tympanic membrane, 
and worsening hearing loss in the right ear. His left ear 
remained  stable.  He  was  referred  to  otolaryngology, 
where a pressure equalization tube was placed in the right 
ear due to eustachian tube dysfunction secondary to radia-
tion therapy.
Case Study 2
This patient is a 58 yr-old male treated for squamous 
cell carcinoma of the right tonsil (stage IVa). The planned
chemotherapy regimen included three doses of 100 mg/m2
of cisplatin on days 1, 22, and 43 with concurrent head 
and neck radiation over 7 wk. At the audiometric baseline 
evaluation,  he  presented  with  normal  hearing  through 
2,500 Hz sloping to a moderately-severe hearing loss at 
8,000  Hz  with  a  high-frequency  limit  of  hearing  of 
10,000 Hz in both ears. He reported bilateral low-level 
constant  tinnitus.  Otoscopy  and  tympanometry  were 
within normal limits. Following his first dose of cisplatin 
(cumulative  dose  =  200  mg),  he  became  neutropenic, 
which resulted in a 2 wk delay in his cisplatin treatment. 
Before  the  second  dose  of  cisplatin,  the  audiologist 
detected ASHA-significant hearing changes from 3,000 
to 10,000 Hz in the right ear and 3,000 to 8,000 Hz in the 
left ear in the presence of normal otoscopy and tympa-
nometry.  The  largest  hearing  shift  was  at  3,000  Hz
(+30  dB  average  shift  in  the  left  and  right  ears)  with 
lesser changes (+10 to +15 dB shifts) seen in the higher 
frequencies  (4,000  Hz).  The  patient  reported  using  a 
power drill on concrete without hearing protection follow-
ing his first dose of cisplatin, despite being counseled by 
the audiologist to avoid noise overexposure. Because of 
concern that the noise exposure exacerbated the cisplatin 
effects,  the  patient  was  counseled  again  and  provided 
new hearing protection. The oncology team was notified 
of the hearing changes but counseled the patient to pro-
ceed with cisplatin treatment to give him the best radia-
tion therapy support. He was prepared for the possibility 
that his hearing could worsen. Following the second dose 
of  cisplatin  (cumulative  dose  =  400  mg),  therapy  was 
complicated by an 8 d hospital admission for neutrope-
nia, fever, and chemotherapy-induced nausea/vomiting. 
The 2 wk delay in day 22 of treatment complicated by the 
recent hospital admission resulted in the discontinuation 
of day 43 treatment. A postexposure follow-up examina-
tion was conducted 1 mo following the second dose of 
cisplatin. At that time, ASHA-significant hearing changes
were noted from 2,000 to 10,000 Hz in the right ear and 
2,000 to 8,000 Hz in the left ear compared with baseline 
measurements in the presence of normal otoscopy and 
tympanometry.  He  denied  any  new  noise  exposure. 
Results indicated hearing loss had progressed following 
the second cycle to include hearing changes at 2,000 Hz 
in  both  ears  averaging  +48  dB  shifts.  Hearing  shifts 
3,000 Hz remained stable in both ears. The patient now 87
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reported increased difficulty understanding speech, espe-
cially  women  and  children,  but  denied  other  otologic 
complaints including aural fullness and changes in base-
line tinnitus. A repeat audiological examination was con-
ducted  again  2  mo  following  cessation  of  cisplatin 
treatment  (approximately  6  wk  following  cessation  of 
radiation  therapy)  and  confirmed  continued  hearing 
changes through 2,000 Hz. Following treatment, he pres-
ents with a fairly flat moderately severe to severe hearing 
loss beginning at 2,000 Hz. He feels that his hearing has 
significantly deteriorated since treatment and has been fit 
with bilateral hearing aids. His most recent examination 
by oncology shows that he is disease free.
Clinical Objectives for COMP-VA
Many oncologists strive to provide patient-centered 
chemotherapy treatment. The case studies just presented 
illustrate  how  ototoxicity  monitoring  information  can 
influence counseling, treatment decisions, and utilization 
of  posttreatment  audiological  services  for  individual 
patients. Below,  we  outline six  clinical  objectives  that 
can be met using the COMP-VA program. We envision 
that  these  clinical  objectives  would  be  tailored  to  the 
needs  and  preferences  of  the  audiologists,  oncology 
teams, and individual patients.
  1. Pretreatment ototoxicity risk assessment to demon-
strate the anticipated hearing loss in the conventional 
frequency range as a result of the prescribed cisplatin 
dosing schedule.
  2. Screening for early hearing changes to identify any 
ASHA-significant hearing shift within each patient’s 
individualized SRO, as measured directly using pure-
tone  threshold  testing  or  estimated  using  DPOAE 
testing.
  3. Screening for outer hair cell dysfunction DPOAEs to 
identify early, potentially preclinical damage.
  4. Screen  failure  follow-up  testing  to  determine  the 
extent that hearing changes include frequencies in the 
conventional  audiometric  frequency  range  as  mea-
sured  directly  using  pure-tone  threshold  testing  or 
estimated using DPOAE testing.
  5. Screening for tinnitus to determine whether the drug 
treatment is instigating or exacerbating tinnitus and 
the need for a tinnitus management referral.
  6. Patient  and  provider  education  about  ototoxic-
induced  hearing  and  tinnitus,  synergistic  effects  of 
ototoxins and noise overexposure, and rehabilitative 
solutions to hearing loss and tinnitus.
The Table summarizes the COMP-VA clinical objec-
tives pertinent to identifying and monitoring changes in 
hearing and outer hair cell function (objectives 1–4, listed 
above).  The  objectives  are  described  in  terms  of  the 
stakeholders  requiring  the  data  (who),  the  information 
being gathered (what), point in treatment to employ the 
test (when), basis for interpreting the results (how), and 
the evidence base supporting the test. Tinnitus screening 
and educational clinical objectives (objectives 5 and 6, 
respectively) are not included in the table.
Stakeholders
Cancer treatment and management is obviously com-
plex. Establishing the clinical objectives for ototoxicity 
monitoring collaboratively with the oncology team helps 
ensure that hearing results will be used in combination 
with other routine toxicity monitoring to affect patient 
care.  Additionally,  both  the  oncology  team  and  the 
patient are more likely to support assessments of ototoxic 
symptoms and act on the results and recommendations if 
they are involved in developing individualized ototoxic-
ity monitoring goals. An overarching goal of the COMP-
VA program is to form team relationships among audiol-
ogy  and  oncology,  thereby  improving  communication 
and coordination of care between these services for the 
benefit of Veterans and their families. We begin by defin-
ing the roles of the major program stakeholders.
Audiologist
In general, it is the responsibility of the audiologist to 
provide quality audiological care and to support the hear-
ing healthcare needs of patients. Within the context of an 
ototoxicity monitoring program, this includes educating 
the patient about the potential for cisplatin to cause or 
exacerbate hearing loss and tinnitus. While the oncology 
team mentions the potential for hearing shift during treat-
ment along with a litany of other toxicities, the audiolo-
gist is best able to provide information about the level of 
risk of hearing shift, factors that increase or decrease the 
risk, and options for rehabilitation should hearing shifts 
manifest. Additionally, it is the responsibility of the audi-
ologist to emphasize the importance of using hearing pro-
tection  and  avoiding  loud  noise  during  and  following 
treatment. This was illustrated in one of the case exam-
ples  provided.  Further,  the  audiologist  is  ideally  posi-
tioned to understand how the pre-treatment hearing status 
or treatment-related change in the hearing status of any 
particular  patient  might  affect  that  patient’s  ability  to Objective Who: Stakeholder
What: Description of 
Clinical Objective
When: Timing 
& Patient Status
How: Basis for 
Interpretation
Evidence Base: 
Relevant Citation(s)
1 Patient, audiologist, 
oncologist
Pretreatment risk 
assessment: Predict 
speech frequency shift
Pretreatment 
counseling & 
planning
Baseline behavioral 
audiogram (8 kHz) 
& prescribed cisplatin 
dose
Dille et al., 2012 [1]; 
Dille et al., 2012 [39]
2 Audiologist Screening for outer hair 
cell dysfunction: Detect 
early changes in 
cochlear function
Any monitoring 
appointment
Larger change in 
DPOAE level than 
reference limits
McMillan et al., 
2013 [40]; McMil-
lan et al. [under 
review]
3 Audiologist, 
oncologist
Screening for early 
hearing changes 
(behavioral): Detect 
shift in SRO
Any monitoring 
appointment for 
responsive/reli-
able patient
Audiologist or 
patient-administered 
identification of 
ASHA-significant 
thresholds changes
Fausti et al., 1999 
[19]; Konrad-Martin 
et al., 2010 [5]
Audiologist, 
oncologist
Screening for early 
hearing changes (non-
behavioral DPOAEs): 
Estimate shift in SRO
Any monitoring 
appointment for 
patient unable to 
take behavioral 
hearing test
Baseline behavioral 
audiogram (SRO), 
administered cisplatin 
dose, & DPOAE I/O 
or DPOAE fine step
Dille et al., 2010 [2]; 
Reavis et al., 2011 
[23]; McMillan et al., 
2013 [40]
4 Patient, audiologist, 
oncologist
Screen failure follow-
up testing (behavioral): 
Detect speech fre-
quency shift
Upon screen fail 
for responsive/ 
reliable patient
Behavioral audio-
gram (8 kHz)
Patient, audiologist, 
oncologist
Screen failure follow-
up testing (nonbehav-
ioral DPOAEs): Esti-
mate speech frequency 
shift
Upon screen fail 
for patient unable 
to take behavioral 
hearing test
DPOAE model of 
behavioral audio-
gram (8 kHz)
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communicate. The audiologist is responsible for ensuring 
that the patient can adequately hear important treatment 
information and to provide strategies for effective com-
munication  including  assistive  hearing  devices,  if 
needed. The audiologist will also act as an intermediary 
between  the  patient  and  medical  team  if  the  team 
expresses concern for whether the patient can hear con-
versation adequately. Finally, it is the responsibility of 
the audiologist to identify those patients who need post-
treatment support to address their hearing loss and tinni-
tus, which may include the acquisition of hearing aids. 
Patients undergoing cisplatin chemotherapy encounter a 
complex array of medical, psychological, and social chal-
lenges. The audiologist could work with the patient to set 
up  audiology  appointments  and  check  back  with  the 
patient if electronic medical records indicate the appoint-
ment was not kept. All aspects of the audiologist’s role 
just  defined  are  consistent  with  ASHA  accepted  care 
guidelines  [20]  and  AAA  position  statements  [26]  for 
ototoxicity monitoring. Providing real-time information 
about ototoxicity and aural rehabilitation to the patient 
and medical team helps to achieve audiological care that 
is consistent with these guidelines and promotes the high-
est possible posttreatment quality of life.
Oncologist
The oncologist has the complex goal of balancing 
treatment needs with side-effect management. Working 
together  with  the  audiologist,  the  oncologist  will  gain 
greater  insight  into  the  adverse  effects  of  cisplatin  on 
communication and, through these interactions, will gain 
an understanding of the benefits and limitations of current
Table.
Description of proposed comprehensive ototoxicity monitoring program for Department of Veterans Affairs (COMP-VA) clinical objectives 1–4. 
Table includes stakeholders in program (who), description of objective (what), implementation time (when), interpretation (how), and relevant 
citations (evidence base).
ASHA = American Speech-Language-Hearing Association, DPOAE = distortion-product otoacoustic emission, I/O = input-output, SRO = sensitive range for ototoxicity.89
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rehabilitation options for the treatment of hearing loss 
and tinnitus. While hearing aids improve hearing dramat-
ically, mostly by increasing the level of soft sounds in the 
environment, they do not fully recover hearing that is 
lost. Damage to outer hair cells from cisplatin changes 
above-threshold  sound  processing  in  a  way  that  can 
reduce frequency contrasts important for distinguishing 
speech  sounds  and  can  narrow  the  range  of  tolerable 
sound levels. These problems can influence the ability of 
an  individual  to  understand  speech  and  obtain  benefit 
from hearing aids. Further, a growing body of literature 
suggests that peripheral hearing loss leads over time to 
major changes in auditory brainstem structures and neu-
rochemistry—changes that have been linked to impaired 
auditory temporal processing in animal models [35–37]. 
While it is difficult to determine using clinical methods 
the  extent  that  frequency  tuning,  perceptual  loudness 
growth, and temporal processing are impaired, it is clear 
that the speech signal processed by a hearing aid and then 
an impaired ear can be substantially degraded. Perhaps 
for this reason and/or because of barriers to health pro-
motion that are not unique to hearing health, hearing aid 
use is only about 20 percent among the general popula-
tion for those with hearing loss [38]. For professionals 
who are not audiologists, gaining a deeper understanding 
of the importance of preserving hearing, when possible, 
cannot be underestimated. Finally, the oncologist will be 
made  aware  of  each  patient’s  risk  for  hearing  change 
based on pretreatment information and will be provided 
with real-time information about cisplatin ototoxicity at 
each treatment interval. Armed with this information, the 
oncologist can consider changing the drug to one that is 
less ototoxic, modify the drug dosage, discontinue treat-
ment and, if no ototoxicity is noted, have greater confi-
dence that hearing after treatment will be spared.
Patient
Family members often report that Veterans with hear-
ing loss underestimate the amount of communication dif-
ficulty they have. The patient should be made aware that 
chemotherapy treatment may worsen their hearing during 
and sometimes months following treatment. For patients 
who already have a preexisting hearing loss, a further 
decrease in hearing from cisplatin may be very detrimen-
tal  to  communication.  Combining  severe  illness  with 
already compromised communication may lead to feel-
ings  of  isolation  and  depression  and  potentially  affect 
conversations pertaining to medical treatment planning. 
When tumor response to cisplatin is good, but ototoxic 
side  effects  are  increasing,  we  have  seen  patients  and 
oncology teams opt to change the treatment regimen. For 
other patients, the primary goal may be to treat the cancer 
in  the  most  aggressive  way  possible.  Therefore,  it  is 
essential  that  the  audiologist,  oncologist,  and  patient 
work together as a team to ensure fully informed deci-
sions  relating  chemotherapy treatment  and  its  ototoxic 
side  effects  are  made.  We  propose  that  rehabilitative 
options  be  discussed  whenever  ototoxic  changes  are 
found.  Investments  made  by  the  audiologist  in  patient 
education may help the Veteran and family members to 
move more smoothly through cancer treatment. As they 
begin to consider future audiological services, they will 
be better prepared for various audiological outcomes.
Clinical Objective 1: Pretreatment Ototoxicity 
Risk Assessment
One clinical objective of an ototoxicity monitoring 
program is to obtain a measure of an individual patient’s 
susceptibility  to,  or  conversely  tolerance  for,  ototoxic 
damage. This information is used for two fundamental 
purposes. First, it can be used by oncology and audiology 
to predict, on an individual patient-ear basis, the dose at 
which a Veteran is most likely to have a significant hear-
ing shift. This represents an extremely valuable tool for 
patient counseling. Armed with this individualized infor-
mation, the audiology/oncology team can tailor discus-
sions about the potential for cisplatin ototoxicity. Second, 
this information will provide oncology with a truly indi-
vidualized  treatment-ototoxicity  profile,  which  could 
potentially assist with treatment planning that considers 
the balance between a curative approach and quality of 
life outcomes following treatment. Finally, this type of 
evidence-based approach provides some guidance for the 
allocation  of  audiological  resources.  For  example,  this 
model indicates that some patients with particularly poor 
hearing  might  require  less  frequent  monitoring  than 
every dose because they are unlikely to have hearing shift 
until cisplatin cumulative dose rises to high levels.
We propose the oncologist be provided a series of 
prediction audiograms using the planned cisplatin dosing 
regimen  (dashed  lines).  The  patient’s  actual  baseline 
audiogram (solid line) would be provided on the same 
graph with gray shading indicating the “speech banana.” 
Figure 2 shows data using this format from case study 1. 
This model of conventional frequency pure-tone thresholds
uses cisplatin dose and threshold information from the Figure 2.
Pretreatment risk assessment audiograms using threshold 
information from case study 1. Series of prediction audiograms 
were generated using planned cisplatin dosing regimen 
(dashed lines) and patient’s actual baseline audiogram (solid 
line) in decibels hearing level (dB HL) shown as function of test 
frequency. Gray shading indicates “speech banana” with pho-
nemes. This model of conventional frequency thresholds 
yielded overall accuracy of 4.9 to 8.0 dB prediction error.
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preexposure audiogram provided by the audiologist. The 
model yielded an overall accuracy of 4.9 to 8.0 dB pre-
diction error when tested against actual pure-tone thresh-
old shifts observed in the functional speech frequency 
range [39]. Since most practitioners and patients remain 
most interested in changes that might occur in the future 
should treatments continue, future work will extend the 
predictive model throughout the conventional audiogram 
(2,000 Hz).
Clinical Objective 2: Behavioral Screening for Early 
Hearing Changes
For  the  purposes  of  COMP-VA,  the  screening  for 
early  hearing  changes  identifies  any  ASHA-significant 
pure-tone threshold shifts within each patient’s individu-
alized  SRO  measured  using  1/6th-octave  frequency 
increments. This behavioral protocol of the seven highest 
frequencies heard by an individual patient in each ear is 
operationally defined by a pure-tone threshold no higher 
than 100 dB SPL. The SRO is not a set frequency range 
that is tested on everyone. Rather the range varies across 
patients depending on their preexposure hearing ability, 
but in most Veterans includes some extended high fre-
quencies (>8,000 Hz). The rationale is that this approach 
will  sometimes  allow  chemotherapy  treatment  to  be 
reconsidered before a handicapping hearing loss occurs, 
which is generally considered one that affects frequen-
cies at and below about 4,000 Hz. Past reports suggest 
that this individualized SRO approach is fast, yet cap-
tures early ototoxic changes. Each patient’s individual-
ized (by ear) SRO can be monitored for signs of hearing 
loss progression over many doses by expanding the range 
when thresholds can no longer be obtained at a limit of 
100 dB SPL.
A graph of SRO thresholds for each ear that includes 
each monitoring visit (designated by the corresponding 
cumulative  cisplatin  dose)  will  be  provided.  Figure  3
shows data using this format for a single ear from case 
study 1. SRO thresholds are provided in decibels SPL as 
a function of frequency. The bold line indicates the base-
line evaluation while the dotted line indicates the evalua-
tion associated with 190 mg of cisplatin. The gray line 
indicates  a  monitoring  result  with  ASHA-significant 
threshold shifts, prompting an examination of the con-
ventional  audiometric  frequency  range.  Otoscopy  and 
tympanometry results are used to help rule out a conduc-
tive component to the loss.
Clinical Objective 3(a): Screening for Outer Hair Cell 
Dysfunction
A graph of DPOAE level shifts superimposed on our 
newly developed test-retest reference limits will be pro-
vided to the audiologist [40]. The graph will indicate any 
changes in the number of valid responses at the monitor 
test compared with baseline, as a function of f2 frequency 
and dose. Figure 4 shows data using this format from the 
patient presented in case study 1, with DPOAE level in 
dB change from baseline as a function of f2 frequency. 
This  patient  had  a  DPOAE  level  decrement  that  was 
greater than the test-retest reference limits (gray fill) fol-
lowing his initial cumulative cisplatin dose of 190 mg 
(black line) at the highest frequencies. There was also a 
large  increment  (DPOAE  amplitude  increased)  at  this 
early dose at around 3,000 Hz. This change preceded any 
significant hearing changes, consistent with the view that 
DPOAEs provide early evidence of changes in cochlear 
health. Experience has shown that increments as well as 
decrements  can  be  indicative  of  damage  and  a  better 
understanding  of  the  basis  for  the  increments  can  be Figure 3.
Behavioral screening for early hearing changes using sensitive 
range for ototoxicity (SRO) protocol obtained from case study 1. 
SRO thresholds are provided in decibels sound pressure level 
(dB SPL) as function of frequency. Bold line indicates baseline 
evaluation, while dotted line indicates evaluation associated 
with 190 mg of cisplatin. Gray dotted line indicates monitoring 
result with American Speech-Language-Hearing Association 
significant threshold shifts, prompting examination of conven-
tional audiometric frequency range. Otoscopy and tympanometry
results are used to help rule out conductive component to loss.
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obtained  by  DPOAE  source  separation  [41],  which  is 
possible to do if DPOAEs are collected using a fine f2-
step DPOAE-gram protocol. At a cumulative dose of 380 
mg (dotted line), DPOAEs had decreased over a wide 
range of frequencies, with decrements at several frequen-
cies extending beyond the reference limits. To be inter-
preted  as  valid  responses  capable  of  providing 
monitoring data, DPOAEs levels must be greater than the 
combined noise and distortion by at least 6 dB and tym-
panometry results must be normal. Downward pointing 
triangles at the bottom of the graph indicate frequencies 
that were valid at baseline but failed the signal-to-noise 
ratio criteria because of a low amplitude response at a 
given monitoring visit (indicated by row). Upward point-
ing triangles show frequencies 
Figure 4.
Data from case study 1 in which distortion-product otoacoustic 
emission (DPOAE) level change (in decibels) from baseline is 
shown as function of f2 frequency measured in fine (1/48-
octave) frequency steps. Test-retest reference limits obtained 
using same test protocol but on similarly aged subjects with no 
exposure to cisplatin are shown (gray fill). DPOAE level decre-
ment was greater than test-retest at highest frequencies following
initial cumulative cisplatin dose of 190 mg (black line). Note also 
large increment (amplitude increased) at around 3,000 Hz. At 
cumulative dose of 380 mg (dotted line), DPOAEs decreased 
over wide range of frequencies, with decrements at several fre-
quencies extending beyond reference limits. Downward point-
ing triangles at bottom of graph indicate frequencies valid at 
baseline but were low amplitude response at monitoring visit 
(indicated by row). Upward pointing triangles show frequencies 
that gained response or showed increment beyond reference 
limits compared with baseline test. Otoscopy and tympanometry
results are used to help rule out conductive component to loss.
that gained a response or 
showed an increment beyond the reference limits com-
pared with the baseline test.
Clinical Objective 3(b): Nonbehavioral (DPOAE) 
Screening for Early Hearing Changes
ASHA-significant pure-tone threshold shifts within 
the SRO can also be estimated using our validated multi-
variate algorithm combining DPOAE test-retest data with 92
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information from the baseline hearing test and the cumu-
lative  cisplatin  dose,  the  ototoxicity  risk  assessment. 
COMP-VA will incorporate our best-performing DPOAE 
model [42], which uses data collected from DPOAE I/O 
functions  near  the  DPOAE  high-frequency  limit  of  a 
valid  response.  Figure  5  shows  data  obtained  in  this 
manner with DPOAE output level plotted as a function of 
stimulus input level (L2). Data are presented for the same 
ear as shown previously from case study 1. Each curve in 
the figure corresponds to a monitor visit with the cumula-
tive dose indicated. Any measurement that fails to meet 
criteria for a valid response (level must be greater than 
the combined noise and distortion by at least 6 dB) is 
indicated by an “X” on the figure corresponding to that 
input level. The gray line identifies the monitor visit at 
which  an  estimated  ASHA-significant  threshold  shift 
occurs within the SRO, which would prompt an examina-
tion  of  the  conventional  audiometric  frequency  range. 
Since these data are from a research subject, we have 
both  behavioral  and  DPOAE  data  at  each  monitoring 
visit. In this case, the DPOAE algorithm correctly identi-
fied the ASHA-significant hearing shift at 380 mg. Oto-
scopic and tympanometric results were used to rule out a 
conductive component to the loss.
Also evident in Figure 5 are substantial changes in 
DPOAE threshold at input levels from 35 to 45 dB SPL 
with  the  patient’s  first  dose  (190  mg).  These  DPOAE 
input  level  changes  accompanied  hearing  changes  that 
were not clinically significant (5 dB), which simultane-
ously shows the potential value of DPOAEs as an early 
warning of imminent hearing change and illustrates the 
clinical utility of our multivariate model. In the absence 
of the model, it would be very difficult to know whether 
the observed DPOAE changes at 190 mg were significant 
with respect to functional hearing.
At this point, DPOAE I/O level changes identify a 
change  in  the  SRO  frequencies  capitalizing  on  early 
detection. A natural extension of this approach we intend 
to develop is a DPOAE model of behavioral thresholds in 
the speech frequency range.
Clinical Objective 4: Screen Failure Follow-Up Testing
Screen failures (for screening using behavioral SRO 
testing,  DPOAE-gram  testing  or  DPOAE  I/O  function 
testing) require the audiologist to complete a test of air 
conduction thresholds within the conventional frequency 
range when the patient is able to provide a reliable test. 
(Bone conduction thresholds are also tested at this point 
if tympanometry is abnormal.) 
Figure 5.
Distortion-product otoacoustic emission (DPOAE) level plotted 
as function of L2 stimulus input level for f2 of 5,040 Hz from 
case study 1 stratified by cumulative drug dose. Measurements 
failing to meet criteria for valid response of +6 dB greater than 
combined noise and system distortion are indicated by “X” on 
figure corresponding to that input level. Gray line identifies 
monitor visit at which estimated American Speech-Language-
Hearing Association-significant threshold shift will occur within 
sensitive range for ototoxicity using ototoxicity risk assessment. 
DPOAE level changes at cisplatin dose of 190 mg to inputs of 
35–45 dB sound pressure level (SPL) were not clinically signifi-
cant (5 dB). Otoscopic and tympanometric results were used 
to rule out conductive component to loss.
This additional testing is 
done to determine the extent that hearing changes include 
speech frequencies and to rule out or quantify any con-
ductive contribution to the loss. The main reason for this 
is that oncologists typically are not willing to withhold or 
change  treatment  based  on  hearing  loss  that  does  not 
threaten  speech  communication.  It  is  not  clear  at  this 
point whether oncologists treating cancer in adults would 
be willing to change treatment based on a physiological 
measure of ototoxicity such as a DPOAE.
Screen failure follow-up testing is best done at the 
same  time  as  the  positive  test  results  are  obtained.  A 
COMP-VA  graph  will  show  conventional  frequency 
thresholds for each ear corresponding to each monitoring 93
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visit in which this test was done, generally at baseline 
and following a screen failure. Figure 6 shows data using 
this format with the monitor visit designated by the corre-
sponding cumulative cisplatin dose. Data are for the same 
ear previously shown for case study 1. A comparison of 
Figure  6  with  Figure  2  reveals  close  correspondence 
between the subject’s predicted and actual loss at 380 mg.
The chemotherapy regimen was changed from cisplatin 
to  carboplatin  following  this  hearing  change  based  on 
input from the oncology team, audiologist, and patient. 
Data are collected in SPL and converted to show conven-
tional  frequency  thresholds  in  decibels  hearing  level 
(HL)  in  order  to  be  consistent  with  a  typical  clinical 
audiogram. Research data are shown for conventional-
frequency thresholds tested only down to 2,000 Hz; how-
ever,  we  propose  testing  down  to  500  Hz  if  possible, 
depending on ambient noise conditions on the ward.
Other Elements of COMP-VA
Tinnitus Ototoxicity Monitoring Interview
The  Tinnitus  Ototoxicity  Monitoring  Interview 
(TOMI) (Appendix, available online only) is designed to 
be given at the baseline visit and at each monitor visit in 
which the patient reports a change in tinnitus. The TOMI 
was developed by Dr. James Henry as a clinical tool to 
detect tinnitus onset or changes in the tinnitus percept 
during  treatment.  Portions  of  the  TOMI  were  adapted 
from the TRT Initial Interview [43]. The TOMI is a 1-page
instrument that can be completed within minutes. Ideally, 
the TOMI should be administered by an audiologist or 
otolaryngologist. However, because it is fully scripted, 
the TOMI can also be administered by a nurse or other 
healthcare  professional  who  may  not  be  familiar  with 
clinical  tinnitus  issues,  in  which  case  the  patient’s 
responses should be reviewed by an audiologist or ear, 
nose, and throat physician.
Testing on Oncology Ward Using COMP-VA
Hospital noise comes from multiple sources that all 
combine into an overall ambient noise level on the treat-
ment  unit.  The  equivalent  A-weighted  noise  level 
(LAEQ)  has  been  measured  in  hospital  wards  and 
reported to be in the range of 40 to 46 dB with instanta-
neous peaks (LCPK) exceeding 90 dB [44]. Gordon et al. 
reported that Portland VAMC oncology ward noise mea-
surements in 1/3-octave frequency bands did not exceed 
37.5 dBA at 500 Hz, 35 dBA at 1,000 Hz, 36 dBA at 
2,000 Hz, and 32 dBA 
Figure 6.
Screen failure follow-up testing done at same time as hearing 
change to determine extent that hearing changes include fre-
quencies within conventional audiometric frequency range. This 
graph, similar to an audiogram, plots conventional frequency 
(≤8,000 Hz) as function of audiometric threshold using data from 
case study 1, stratified by cumulative drug dose. Comparison of 
Figure 6 with Figure 2, using same ear, reveals close correspon-
dence between subject’s predicted and actual loss at 380 mg. HL =
hearing level.
at frequency bands greater than 
3,000 Hz [45].
We applied MPANLs for audiometric test rooms [46] 
to  the  treatment  unit  for  the  purposes  of  COMP-VA. 
MPANLs are only reported up to 8,000 Hz and do not 
include  MPANLs  for  the  Sennheiser  HDA-200  ear-
phones, used with the OtoID. We have used the published 
Sennheiser passive attenuation data along with the pub-
lished computational  formula in  the  ANSI  standard  to 
develop  estimates  of  MPANLs  for  the  HDA-200  ear-
phones from 125 to 16,000 Hz in 1/3-octave frequency 
bands. In order to complete this calculation, we extrapo-
lated  data  for  frequencies  above  8,000  Hz.  Figure  7
shows  the  results  of  our  calculated  MPANLs  for  the 
Sennheiser  HDA-200  series  earphones  (circles),  insert 
earphones (triangles), and hospital ward noise (asterisk) 
derived from Gordon et al. for frequencies 125–16,000 Hz
[45]. The Sennheiser HDA-200 earphones are usable for 
threshold  determination  at  frequencies  above  1,000  Hz, 94
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with the possible exception of 1,500 Hz. The insert ear-
phones are useable at all test frequencies.
Furthermore, Gordon et al. reported on the use of cir-
cumaural  and  in-the-ear  earphones  for  high  frequency 
testing in the sound booth as well as on
Figure 7.
Maximum permissible ambient noise levels (MPANLs) (in deci-
bels re: 20 µPa, American National Standards Institute S3.1–
1999) for audiometric test room is shown as function of fre-
quency when HDA 200 (circles) circumaural earphones and 
Etymotic ER2 (triangles) earphones are used. Hospital noise 
(asterisk) levels as function of frequency measured in 1/3-
octave frequency bands (Gordon et al., 2005 [45]) are also 
shown. Data show that reliable behavioral hearing thresholds 
can be obtained for frequencies above 2,000 Hz in most cir-
cumstances. In addition, room noise using OtoID is measured 
just before presentation of each tone as extra measure that 
noise levels in room are well controlled. Using insert earphones 
for collecting distortion-product otoacoustic emissions, all f2 fre-
quencies can be used.
 the hospital ward 
[45],  reporting  “test-retest  reliability  was  found  to  be 
good for the KOSS circumaural earphones and the ER4-B
insert earphones for both sound booth and hospital ward 
settings.”  Dille  et  al.  reported  on  retest  comparisons 
using the OtoID over 3 d on 40 subjects both young and 
older  with  and  without  hearing  loss  tested  in  a  sound 
booth and on the hospital ward [17]. Ninety-five percent 
of all tests were within ±5 dB with no systematic effect of 
location or subject. These results indicate that ward noise 
is not likely to interfere with collecting reliable threshold 
data when circumaural, supra-aural, or in-the-ear trans-
ducers are used and efforts are made to control or segre-
gate ambient noise from the test environment. Further, 
the  OtoID is capable  of  measuring room  noise  during 
testing and is designed to halt testing should noise in the 
room exceed preset limits.
Our  DPOAE  measurements  are  acquired  using  an 
insert  probe  with  similar  attenuation  characteristics  as 
insert earphones. MPANLs for DPOAE testing using an 
insert probe with sufficient averaging were estimated to 
be  55  dBA  for  frequencies  2,000 to  6,000  Hz  [47], 
which easily exceeds the ambient noise levels on the hos-
pital ward [44–45]. The measurement of DPOAE data 
involves signal averaging in order to improve the signal-
to-noise ratios of the measurement. The number of aver-
ages that we take is adjusted in order to meet the desired 
noise floor of our measurement, which we have set to a 
level near the approximate level of our system distortion. 
This response-based averaging time is allowed to continue
up to a predetermined halting time-out. An analysis of the 
average recording time for tests completed on the ward
demonstrate  that  the  desired  noise  floor  is  achieved  in 
almost all cases before time-out is reached. This is an addi-
tional  indicator  that  acceptable  signal-to-ambient-noise 
ratios exist for our DPOAE testing in the hospital wards.
OVERVIEW OF TESTING PROTOCOL AND 
SCHEDULE
The proposed protocol for accomplishing objectives 
1–4 is summarized schematically in Figure 8. The flow-
chart demonstrates how the COMP-VA monitoring pro-
tocol  is  used  for  detecting hearing  and  outer  hair  cell 
function  changes.  Pretreatment  tests  include  otoscopy, 
tympanometry, and air conduction testing in conventional 
and extended high frequencies and SRO is determined 
for subsequent testing. Pretreatment risk calculations are 
done  and  used  for  educational  and  patient  counseling 
purposes and, potentially, to help determine how to allo-
cate  hearing  screening  resources.  Screening  is  ideally 
done just before each cisplatin infusion because changes 
in medication can be considered before the next dose. 
Screenings  minimally  include  the  SRO  audiogram  for 
responsive/reliable patients. A DPOAE-gram is also rou-
tinely done as a means to detect ototoxic changes early. 
Using the DPOAE-gram, DPOAE level changes are cal-
culated relative to baseline measures and compared with 
our reference limits to determine whether the changes are 
greater than those attributable to normal test-retest vari-
ability. DPOAE I/O functions are reserved for patients 
who are too sick to provide a reliable hearing test. The 95
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DPOAE I/O function results are compared with the baseline
test, and differences are 
Figure 8. 
Flowchart demonstrating how comprehensive ototoxicity monitoring program for Department of Veterans Affairs (COMP-VA) moni-
toring protocol is used for detecting hearing and outer hair cell function changes. Pretreatment tests include otoscopy, tympanome-
try, distortion-product otoacoustic emission (DPOAE) testing, and air-conduction testing in conventional and extended high 
frequencies, and sensitive range for ototoxicity (SRO) is determined for subsequent testing. From these tests, pretreatment risk cal-
culation is done for educational and patient counseling purposes and may prove helpful when planning professional resources. 
Screenings minimally include SRO audiogram for responsive/reliable patients and DPOAE level plotted as a function of f2 frequency 
to detect early ototoxic changes. From DPOAE level plotted as a function of f2 frequency, DPOAE level changes are calculated rela-
tive to baseline measures and compared with our reference limits to determine whether changes are greater than those attributable 
to normal test-retest variability and DPOAE input-output functions (obtained from multiple levels) are reserved for patients who are too 
sick to provide reliable hearing test. Any screen failure requires follow-up testing, ideally done using behavioral hearing test.
used as inputs to our validated 
algorithm that identifies ASHA-significant shifts in the 
SRO. Any screen failure requires follow-up testing, ide-
ally done using a behavioral hearing test.
COMP-VA advocates a testing regimen that includes 
a baseline (preexposure to cisplatin) evaluation, monitor 
evaluations before each cisplatin treatment, and a follow-
up evaluation after the regimen is completed. It is often 
most convenient for the patient to conduct monitor evalua-
tions  during  hydration  just  before  the  next  cisplatin 
administration. This allows the oncologist at least some 
time to consider treatment changes should a hearing shift 
be discovered. Posttreatment regimen evaluations should 
be conducted in a timely fashion so that new or exacer-
bated audiological changes can be promptly addressed.
DISCUSSION
Both ASHA and AAA professional organizations pro-
vide position statements to the community of audiologists96
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regarding the necessity and implementation of ototoxic-
ity monitoring. Both position statements suggest that oto-
toxicity  monitoring  may  not  prove  actionable  to 
oncologists  because  cancer  treatment  objectives  are  in 
many cases immutable. This has not been our experience. 
Head and neck cancers tend to respond well to treatment 
while, in our Veteran population, lung cancer outcomes 
are not as favorable. Our oncologists consider the effect 
of communication deficits for Veteran survivors of can-
cer, as well as those in palliative care. They are interested 
in controlling treatment-related hearing loss and are will-
ing to change treatment regimens or chemotherapeutic 
agents if it is medically responsible to do so when ototox-
icity is discovered.
Since Veterans enter treatment with substantial hear-
ing loss, ototoxicity monitoring has the potential to main-
tain  quality  of  life  following  treatment.  This  is 
particularly true when the audiologist becomes an advo-
cate for hearing preservation and rehabilitation. Months 
spent  educating  the  Veteran patient  on  communication 
effects of hearing loss, avoidance of noise overexposure 
and, when necessary, timely access to assistive devices 
provide a rationale and motivation for hearing aids after 
treatment. ASHA suggests that audiologists are “ethically 
bound” to begin rehabilitation following treatment [20, p. 
10]. We enthusiastically agree and have built this into our 
program.
While COMP-VA is consistent with published oto-
toxicity monitoring recommendations in many ways, it 
differs  from them  in  important ways.  One particularly 
important distinction is that both organizational position 
statements suggest that the best monitoring approach is 
through  a  comprehensive  auditory  evaluation  before 
monitoring (baseline). They advocate that testing should 
minimally  include  pure-tone  air-  and  bone-conduction 
audiometry, otoscopy, tympanometry, and speech mea-
sures, with the rationale that to evaluate change, compre-
hensive  evaluations  are  necessary.  It  is  true  that  the 
functional effect of pure-tone change in the conventional 
frequencies will be expressed in speech results. However, 
it  is  unlikely  that  rehabilitation  can  be  effectively 
addressed during treatment beyond an assistive device. 
Cancer treatment is fairly short-term, lasting sometimes 
only months. By the nature of its screening protocols, 
COMP-VA suggests postponing rehabilitation until treat-
ment has been completed. However, we do agree that any 
testing from which comparisons will be made must be 
done at baseline. We advocate the time-efficient screen-
ing SRO protocol at baseline combined with tympanome-
try and otoscopy to rule out ear disease and obstruction. 
If otoacoustic emission testing is anticipated during treat-
ment, it also must be done at the baseline visit in order to 
have a basis for meaningful interpretation of the findings.
Guidelines from ASHA and AAA, published 15 yr 
later, do not promote SRO testing; however, they do sup-
port  the  use  of  high  frequency  audiometry.  The  SRO 
omission may have been the result of the lack of instru-
ment availability for 1/6-octave testing at the time. Both 
sets of guidelines recognize that DPOAE testing is a sen-
sitive  measure of outer hair cell function that may  be 
especially important for the testing of elderly and hearing 
impaired patients and that tinnitus information obtained 
during treatment ought to be methodically obtained, con-
sistent with our recommendations.
Despite substantial evidence and professional guide-
lines for alleviating preventable hearing loss, ototoxicity 
monitoring remains underutilized in the VA. In 2008, a 
national survey of VA audiologists from approximately 
40 medical centers confirmed several barriers to wide-
spread implementation, with common responses being the
lack of (1) appropriate instrumentation with which to per-
form ototoxicity testing in varied test locations; (2) access
to specific, evidence-based protocols suitable for testing 
all  patients  regardless  of  illness;  and  (3)  personnel 
resources to perform labor-intensive ototoxicity monitor-
ing protocols.
COMP-VA attempts to address each of these barriers 
with clinically appropriate and efficient evidence-based 
protocols and instrumentation. The efficiencies we pro-
pose  were  designed  to  provide  systematic  monitoring 
throughout  treatment,  while  conserving  audiological 
resources, now a necessary feature when introducing a 
new  clinical  service  to  VA.  Aspects  of  the  program 
include  the  OtoID,  a  relatively  low-cost,  high-fidelity 
portable audiometer that has a wide test-frequency range, 
can test in fine frequency steps using manual or auto-
mated  modes,  and  mitigates  the  potential  influence  of 
ambient noise on the test. Using evidence-based behav-
ioral  and  objective  test  protocols,  COMP-VA provides 
up-to-the-minute  estimates  of  ototoxicity  before  the 
patient’s next treatment, which allows for timely consid-
eration  of  treatment  changes.  Proposed  objective  tests 
include methods for identifying outer hair cell changes 
and predicting audiogram changes using DPOAEs.
Further work to accomplish includes expanding the 
speech frequency prediction model to include frequencies97
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below 2,000 Hz. Early identification of hearing shift is 
important. However, oncologists tell us that, in addition, 
they would like to know when communication will be 
significantly affected. This could provide them an oppor-
tunity to give additional doses that potentially bring the 
Veteran closer to a cure without significantly affecting 
quality of life following treatment.
A limitation to our current DPOAE-gram screening 
protocol is that the preliminary DPOAE reference limits 
do not extend testing into the time period that reflects cis-
platin treatment, which often occurs over several months. 
This  is  a  common  problem  among  DPOAE  test-retest 
variability studies, in which retests extend only out to 
approximately 15 d. The ramification is that COMP-VA 
retest  reference  limits  do  not  account  for  increases  in 
variability over time. A model based on a meta-analysis 
of the published DPOAE test-retest variability is being 
developed that will extrapolate the variability estimates 
over longer durations.
Having DPOAE prediction indicators in a variety of 
important frequency intervals (extended high frequency 
and speech frequency) could lend confidence to an indi-
cation that hearing has changed and to a decision to con-
tinue  to  treat  or  to  hold  treatment  pending  behavioral 
hearing results. Planned research will therefore include 
DPOAE prediction of speech frequency change, as well 
as presence/absence of SRO shifts.
CONCLUSIONS
A successful ototoxicity monitoring program requires
team relationships between audiology and oncology so 
that  communication  between  services  can  be  efficient. 
Monitoring  that  can  be  conducted  almost  exclusively 
chairside addresses issues of limited sound booth avail-
ability and the need to “add on” testing appointments, often 
required  for  ototoxicity  monitoring  programs.  Presenting
clear, reliable, easily understood and evidence-based test 
results will improve communication and trust within the 
team, thus enhancing therapeutic planning, coordination 
of care, and informed decision-making. Finally, having a 
robust ototoxicity monitoring program like COMP-VA in 
place also ensures that an audiologist who has developed 
a working relationship with the patient during multiple 
testing sessions is also able to provide posttreatment sup-
port  and  encouragement  should  rehabilitation  become 
necessary after treatment.
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